• Sponsored Content

BPI Staff

July 22, 2019

1 Min Read

2019-BIO-Theater-Dailies-Celonic-300x168.pngCelonic CEO Konstantin Matentzoglu spoke to Dan Stanton at the BPI Theater at BIO (Tuesday, 4 June 2019) about the state of the biologics contract development manufacturing organization (CDMO) industry and his company’s ambition in the space. He divulged details of the firm’s recent €50 million ($56 million) expansion at its Heidelberg, Germany site, adding 4,500 square meters of cleanroom space to feed the increased demand for biologics manufacturing services, and spoke of a similar investment at a site in Basel to propel Celonic into the burgeoning cell and gene therapy space.

You May Also Like